Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851207 | 0.89 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL3851702 | 0.89 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL3852603 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL4915985 | 0.80 | KDM4E (0.41) | CHRNB2CHRNA4S1PR3 | |
| SCHEMBL4912545 | 0.80 | KDM4E (0.41) | CHRNB2CHRNA4S1PR3 | |
| Trifluoroacetic Acid SCHEMBL953331 | 0.77 | CHRM2 (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL16464688 | 0.75 | NPC1 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL3852786 | 0.75 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL16464687 | 0.75 | NPC1 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL3852788 | 0.75 | CHRNB2 (0.51) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678169-A1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |